Indeed, our results could suggest that larger tumours, characterised by poorer prognosis for surgical resolution and bearing a higher expression of DRD5 and sst3, could be possibly treated before surgery using alternative DRD agonists (i.e. with high affinity for DRD5) or pasireotide (a multireceptor ligand with affinity for sst1, sst2, sst3 and sst5), insofar the mRNA of these receptors is correctly transcribed to protein, as previously reported in neuroendocrine tumours48. Here, SSTR2 is linked to neoplasm.